Galmed Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report

https://galmedpharma.com  ᛫ 
Last updated December 14, 2019

About Galmed Pharmaceuticals

Company Overview

Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease.Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters.Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to significantly reduce liver fat content as well as improve metabolic parameters associated with fatty liver disease.

Valuation

Employees

CEO

Location

Data Breaches and Security News

Galmed Pharmaceuticals Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Galmed Pharmaceuticals is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Galmed Pharmaceuticals

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Galmed Pharmaceuticals's security performance with other companies